Optimal financing design for drug development firms
Publication date: September 2026 Source: Research Policy, Volume 55, Issue 7 Author(s): Richard T. Thakor, Andrew W. Lo
Record details
Published: 14 July 2026
Source: Research Policy
Category: Research
Topics: Regulation · Healthcare
Retrieved: 14 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
Diagnosing and Calibrating Tool-Call Boundary Drift in Multi-Teacher On-Policy Distillation
HuggingFace Daily Papers · 14 July 2026
Limited awareness of AI regulations among developers raises potential concerns for healthcare rollout
NTU Singapore AI · 15 July 2026
Structural predictors and latent maturity regimes of robotic readiness in global health systems: evidence from machine learning-based latent clustering and class prediction
Frontiers in Robotics and AI · 16 July 2026
Auditing Fairness-Privacy Trade-offs: Subpopulation-Level Effects of Fairness-Enhancing Algorithms
arXiv · 16 July 2026
Concept-Guided Spatial Regularization for World Models in Atari Pong
arXiv cs.AI · 16 July 2026
Diagnosing and Mitigating Thinking Collapse in On-Policy Self-Distillation
arXiv cs.LG · 12 July 2026
How to cite this record
ethics.ai (14 July 2026), “Optimal financing design for drug development firms,” evidence record 2367, https://ethics.ai/record/2367 (originally published by Research Policy).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.